EDGEWELL PERSONAL CARE Co 10-Q for FY2023 Q2
EDGEWELL PERSONAL CARE Co (EPC)
10-Q
2023-05-09
For: 2023-03-31
View Original
Added on
April 08, 2026
About this 10-Q
EDGEWELL PERSONAL CARE Co filed this 10-Q on May 9, 2023, covering the quarter ended March 31, 2023 (FY2023 Q2).
Headline figures
Quarter ended March 31, 2023, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $598.4M
- up 9.3% from $547.7M a year earlier
- Net income
- $19M
- down 18.1% from net income of $23.2M a year earlier
- Diluted EPS
- $0.37
- down 14.0% from $0.43 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________
FORM 10-Q
_______________________________
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the quarterly period ended March 31, 2023
or
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the transition period from _______________ to _______________
Commission File Number: 001-15401
____________________________________________________________________________________________________________
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) | (I. R. S. Employer Identification No.) | |||||||||||||
| (Registrant’s telephone number, including area code) | ||||||||||||||
| (Address of principal executive offices and zip code) | ||||||||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| ☒ | Accelerated filer | ☐ | ||||||||||||
| Non-accelerated filer | ☐ | (Do not check if a smaller reporting company) | Smaller reporting company | |||||||||||
| Emerging growth company | ||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
Common shares, $0.01 par value - 51,173,405 shares as of April 30, 2023.
EDGEWELL PERSONAL CARE COMPANY
INDEX TO FORM 10-Q
| PART I. | FINANCIAL INFORMATION | |||||||
| Item 1. | Financial Statements | |||||||
| Condensed Consolidated Statements of Earnings and Comprehensive Income for the three and six months ended March 31, 2023 and 2022 | ||||||||
| Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 | ||||||||
| Condensed Consolidated Statements of Cash Flows for the six months ended March 31, 2023 and 2022 | ||||||||
| Condensed Consolidated Statements of Changes in Shareholders’ Equity for the three and six months ended March 31, 2023 and 2022 | ||||||||
| Notes to Condensed Consolidated Financial Statements | ||||||||
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | |||||||
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | |||||||
| Item 4. | Controls and Procedures | |||||||
| PART II. | OTHER INFORMATION | |||||||
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | |||||||
| Item 6. | Exhibits | |||||||
| SIGNATURE | ||||||||
2
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
EDGEWELL PERSONAL CARE COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME
(unaudited, in millions, except per share data)
| Three Months Ended March 31, | Six Months Ended March 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Net sales | $ | $ | $ | $ | |||||||||||||||||||
| Cost of products sold | |||||||||||||||||||||||
| Gross profit | |||||||||||||||||||||||
| Selling, general and administrative expense | |||||||||||||||||||||||
| Advertising and sales promotion expense | |||||||||||||||||||||||
| Research and development expense | |||||||||||||||||||||||
| Restructuring charges | |||||||||||||||||||||||
| Operating income | |||||||||||||||||||||||
| Interest expense associated with debt | |||||||||||||||||||||||
| Other expense (income), net | ( | ( | |||||||||||||||||||||
| Earnings before income taxes | |||||||||||||||||||||||
| Income tax provision | |||||||||||||||||||||||
| Net earnings | $ | $ | $ | $ | |||||||||||||||||||
| Earnings per share: | |||||||||||||||||||||||
| Basic net earnings per share | $ | $ | $ | $ | |||||||||||||||||||
| Diluted net earnings per share | $ | $ | $ | $ | |||||||||||||||||||
| Statements of Comprehensive Income: | |||||||||||||||||||||||
| Net earnings | $ | $ | $ | $ | |||||||||||||||||||
| Other comprehensive income (loss), net of tax | |||||||||||||||||||||||
| Foreign currency translation adjustments | ( | ( | |||||||||||||||||||||
Pension and postretirement activity, net of tax of $ | |||||||||||||||||||||||
Deferred gain (loss) on hedging activity, net of tax (benefit) of $ | ( | ||||||||||||||||||||||
| Total other comprehensive income (loss), net of tax | ( | ( | |||||||||||||||||||||
| Total comprehensive income | $ | $ | $ | $ | |||||||||||||||||||
See accompanying Notes to Condensed Consolidated Financial Statements.
3
EDGEWELL PERSONAL CARE COMPANY
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in millions, except share data)
| March 31, 2023 | September 30, 2022 | ||||||||||
| Assets | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ | $ | |||||||||
| Trade receivables, less allowance for doubtful accounts of $5.5 and $3.8 | |||||||||||
| Inventories | |||||||||||
| Other current assets | |||||||||||
| Total current assets | |||||||||||
| Property, plant and equipment, net | |||||||||||
| Goodwill | |||||||||||
| Other intangible assets, net | |||||||||||
| Other assets | |||||||||||
| Total assets | $ | $ | |||||||||
| Liabilities and Shareholders’ Equity | |||||||||||
| Current liabilities | |||||||||||
| Notes payable | $ | $ | |||||||||
| Accounts payable | |||||||||||
| Other current liabilities | |||||||||||
| Total current liabilities | |||||||||||
| Long-term debt | |||||||||||
| Deferred income tax liabilities | |||||||||||
| Other liabilities | |||||||||||
| Total liabilities | |||||||||||
| Shareholders’ equity | |||||||||||
Preferred shares, $ | |||||||||||
Common shares, $ | |||||||||||
| Additional paid-in capital | |||||||||||
| Retained earnings | |||||||||||
Common shares in treasury at cost, | ( | ( | |||||||||
| Accumulated other comprehensive loss | ( | ( | |||||||||
| Total shareholders’ equity | |||||||||||
| Total liabilities and shareholders’ equity | $ | $ | |||||||||
See accompanying Notes to Condensed Consolidated Financial Statements.
4
EDGEWELL PERSONAL CARE COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in millions)
| Six Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Cash Flow from Operating Activities | |||||||||||
| Net earnings | $ | $ | |||||||||
| Depreciation and amortization | |||||||||||
| Share-based compensation expense | |||||||||||
| Loss on sale of assets | |||||||||||
| Defined benefit settlement loss | — | ||||||||||
| Deferred compensation payments | ( | ( | |||||||||
| Deferred income taxes | ( | ( | |||||||||
| Other, net | ( | ( | |||||||||
| Changes in operating assets and liabilities | ( | ( | |||||||||
| Net cash from (used by) operating activities | $ | $ | ( | ||||||||
| Cash Flow from Investing Activities | |||||||||||
| Capital expenditures | ( | ( | |||||||||
| Acquisition of Billie, net of cash acquired | ( | ||||||||||
| Collection of deferred purchase price on accounts receivable sold | |||||||||||
| Proceeds from sale of Infant and Pet Care business | |||||||||||
| Other, net | ( | ( | |||||||||
| Net cash used by investing activities | $ | ( | $ | ( | |||||||
| Cash Flow from Financing Activities | |||||||||||
| Cash proceeds from debt with original maturities greater than 90 days | |||||||||||
| Cash payments on debt with original maturities greater than 90 days | ( | ( | |||||||||
| (Payments) proceeds of debt with original maturities of 90 days or less | ( | ||||||||||
| Repurchase of shares | ( | ( | |||||||||
| Dividends to common shareholders | ( | ( | |||||||||
| Net financing inflow (outflow) from the Accounts Receivable Facility | ( | ||||||||||
| Employee shares withheld for taxes | ( | ( | |||||||||
| Other, net | |||||||||||
| Net cash (used by) from financing activities | $ | ( | $ | ||||||||
| Effect of exchange rate changes on cash | ( | ||||||||||
| Net decrease in cash and cash equivalents | ( | ( | |||||||||
| Cash and cash equivalents, beginning of period | |||||||||||
| Cash and cash equivalents, end of period | $ | $ | |||||||||
See accompanying Notes to Condensed Consolidated Financial Statements.
5
EDGEWELL PERSONAL CARE COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
(unaudited, in millions)
| Common Shares | Treasury Shares | ||||||||||||||||||||||||||||||||||||||||||||||
| Number | Par Value | Number | Amount | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Total Shareholders’ Equity | ||||||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2022 | $ | ( | $ | ( | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
| Net earnings | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustments | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
| Pension and postretirement activity | — | — | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||||||||||||
| Deferred loss on hedging activity | — | — | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||||||||||||
| Dividends declared to common shareholders | — | — | — | — | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||||
| Repurchase of shares | — | — | ( | ( | — | — | — | ( | |||||||||||||||||||||||||||||||||||||||
| Activity under share plans | — | — | ( | — | — | ( | |||||||||||||||||||||||||||||||||||||||||
| Balance as of December 31, 2022 | $ | ( | $ | ( | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
| Net earnings | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustments | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
| Pension and postretirement activity | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
| Deferred gain on hedging activity | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
| Dividends declared to common shareholders | — | — | — | — | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||||
| Repurchase of shares | — | — | ( | ( | — | — | — | ( | |||||||||||||||||||||||||||||||||||||||
| Activity under share plans | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||
| Balance as of March 31, 2023 | $ | ( | $ | ( | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
6
| Common Shares | Treasury Shares | ||||||||||||||||||||||||||||||||||||||||||||||
| Number | Par Value | Number | Amount | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Total Shareholders’ Equity | ||||||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2021 | $ | ( | $ | ( | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
| Net earnings | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustments | — | — | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||||||||||||
| Deferred gain on hedging activity | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
| Dividends declared to common shareholders | — | — | — | — | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||||
| Repurchase of shares | — | — | ( | ( | — | — | — | ( | |||||||||||||||||||||||||||||||||||||||
| Activity under share plans | — | — | ( | — | — | ( | |||||||||||||||||||||||||||||||||||||||||
| Balance as of December 31, 2021 | $ | ( | $ | ( | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
| Net earnings | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustments | — | — | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||||||||||||
| Pension and postretirement activity | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
| Deferred gain on hedging activity | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
| Dividends declared to common shareholders | — | — | — | — | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||||
| Repurchase of shares | — | — | ( | ( | — | — | — | (50.9) | |||||||||||||||||||||||||||||||||||||||
| Activity under share plans | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||
| Balance as of March 31, 2022 | $ | ( | $ | ( | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
See accompanying Notes to Condensed Consolidated Financial Statements.
7
EDGEWELL PERSONAL CARE COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, in millions, except per share data)
Note 1 - Background and Basis of Presentation
Background
Edgewell Personal Care Company and its subsidiaries (collectively, “Edgewell” or the “Company”) is one of the world’s largest manufacturers and marketers of personal care products in the wet shave, sun and skin care, and feminine care categories. With operations in over 20 countries and with products widely available in more than 50 countries.
The Company conducts its business in the following three segments:
•Wet Shave consists of products sold under the Schick®, Wilkinson Sword®, Edge, Skintimate®, Billie®, Shave Guard and Personna® brands, as well as non-branded products. The Company’s wet shave products include razor handles and refillable blades, disposable shave products, and shaving gels and creams.
•Sun and Skin Care consists of Banana Boat® and Hawaiian Tropic® sun care products, Jack Black®, Bulldog® and Cremo® men’s grooming products, Billie women’s grooming products and Wet Ones® products.
•Feminine Care includes tampons, pads, and liners sold under the Playtex Gentle Glide® and Sport®, Stayfree®, Carefree®, and o.b.® brands.
Basis of Presentation
The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its controlled subsidiaries and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) under the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). The preparation of the unaudited Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results may differ materially from those estimates. All intercompany balances and transactions have been eliminated in consolidation and, in the opinion of management, all normal recurring adjustments considered necessary for a fair statement have been included in the interim results reported. The fiscal year-end balance sheet data was derived from audited consolidated financial statements, but do not include all of the annual disclosures required by GAAP; accordingly, these unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited annual consolidated financial statements included in its Annual Report on Form 10-K filed with the SEC on November 16, 2022.
Acquisition of Billie, Inc. On November 29, 2021 (“the Acquisition Date”), the Company completed the acquisition of Billie, Inc. (“Billie”) (the “Acquisition”), a leading U.S. based consumer brand company that offers a broad portfolio of personal care products for women. The results of Billie for the post-acquisition period are included within the Company’s results since the acquisition date. For more information on the Acquisition, see Note 2 of Notes to Condensed Consolidated Financial Statements.
Recently Issued Accounting Pronouncements
In September 2022, the Financial Accounting Standards Board issued Accounting Standards Update 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations". This guidance requires annual and interim disclosures for entities that use supplier finance programs in connection with the purchase of goods and services. These amendments are effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company is assessing the impact, if any, of this guidance on its Consolidated Financial Statements.
8
Note 2 - Business Combinations
Billie Inc.
The Company completed the Acquisition for cash consideration of $309.4 , net of cash acquired. As a result of the Acquisition, Billie became a wholly owned subsidiary of the Company. The Company accounted for the Acquisition utilizing the acquisition method of accounting, which requires assets and liabilities to be recognized based on estimates of their acquisition date fair values. The determination of the values of the acquired assets and assumed liabilities, including goodwill, other intangible assets and deferred taxes, requires significant judgement. The Company has calculated fair values of the assets and liabilities acquired from Billie, including goodwill, intangible assets and working capital. The Company completed the final fair value determination of the Acquisition in the fourth quarter of fiscal year 2022.
The Company used variations of the income approach in determining the fair value of intangible assets acquired in the Acquisition. Specifically, the Company utilized the multi-period excess earnings method to determine the fair value of the definite lived customer relationships acquired and the relief from royalty method to determine the fair value of the definite lived trade name acquired. The Company’s determination of the fair value of the intangible assets acquired involved the use of significant estimates and assumptions related to revenue growth rates, discount rates, customer attrition rates, and royalty rates. Edgewell believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use.
The following table provides the allocation of the purchase price related to the Acquisition based upon the fair value of assets and liabilities assumed:
| Current assets | $ | ||||
| Goodwill | |||||
| Intangible assets | |||||
| Other assets, including property, plant and equipment, net | |||||
| Current liabilities | ( | ||||
| Deferred tax liabilities | ( | ||||
| Cash consideration, net of cash acquired | $ | ||||
The acquired goodwill represented the value of expansion into new categories, markets and channels of trade and is not deductible for tax purposes. The intangible assets acquired consisted primarily of the Billie trade name and customer relationships with a weighted average useful life of 19 years. All assets are included in the Company’s Wet Shave segment.
The following summarizes the company's unaudited pro forma consolidated results of operations for the three and six months ended March 31, 2022, as though the Acquisition occurred on October 1, 2020. The three and six months ended March 31, 2023 include results of Billie over the full periods presented.
| Three Months Ended March 31, 2022 | Six Months Ended March 31, 2022 | ||||||||||
| Pro forma net sales | $ | $ | |||||||||
| Pro forma net earnings | |||||||||||
The unaudited pro forma consolidated results of operations were adjusted by pre-tax amortization expense of $1.3 for the six months ended March 31, 2022. Additionally, pro forma earnings for the three and six months ended March 31, 2022 exclude $1.1 and $7.1 of pre-tax acquisition costs, respectively, as these costs would have been incurred in the prior year. The pro forma earnings were also adjusted to reflect the capital structure as of the Acquisition Date, and all pro forma adjustments have been included with related tax effects. The unaudited pro forma consolidated results of operations is not necessarily indicative of the results obtained had the Acquisition occurred on October 1, 2020, or of those results that may be obtained in the future. Amounts do not reflect any anticipated cost savings or cross-selling opportunities expected to result from the Acquisition.
Note 3 - Restructuring Charges
Operating Model Redesign
In fiscal 2023, the Company is continuing to take actions to strengthen its operating model, simplify the organization and improve manufacturing and supply chain efficiency and productivity. As a result of these actions, the Company expects to incur restructuring charges of approximately $19 in fiscal 2023. The Company incurred restructuring charges as follows:
9
| Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | Six Months Ended March 31, 2023 | Six Months Ended March 31, 2022 | ||||||||||||||||||||
| Severance and related benefit costs | $ | $ | $ | $ | |||||||||||||||||||
| Asset write-off and accelerated depreciation | |||||||||||||||||||||||
| Consulting, project implementation and management, and other exit costs | |||||||||||||||||||||||
Total restructuring (1)(2) | $ | $ | $ | $ | |||||||||||||||||||
(1)Restructuring costs of $0.2 are included within Cost of products sold for both the three and six months ended March 31, 2023.
(2)Restructuring costs of $0.1 are included within Selling, general and administrative expense (“SG&A”) for the six months ended March 31, 2023, and $0.2 for both the three and six months ended March 31, 2022.
| Utilized | |||||||||||||||||||||||||||||||||||
| October 1, 2022 | Charge to Income | Cash | March 31, 2023 | ||||||||||||||||||||||||||||||||
| Severance and related benefit costs | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||
| Asset write-off and accelerated depreciation | ( | ||||||||||||||||||||||||||||||||||
| Consulting, project implementation and management, and other exit costs | ( | ||||||||||||||||||||||||||||||||||
| Total restructuring activities and related accrual | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||
Note 4 - Income Taxes
For the three and six months ended March 31, 2023, the Company had income tax expense of $7.0 and $11.5 , respectively, on Earnings before income taxes of $26.0 and $42.4 , respectively. The effective tax rate for the three and six months ended March 31, 2023 was 26.9 % and 27.0 %, respectively. The difference between the federal statutory rate and the effective rate is primarily due to an unfavorable mix of earnings in higher tax rate jurisdictions.
For the three and six months ended March 31, 2022, the Company had income tax expense of $3.9 and $8.9 , respectively, on Earnings before income taxes of $27.1 and $43.3 , respectively. The effective tax rate for the three and six months ended March 31, 2022 was 14.4 % and 20.5 %, respectively. The difference between the federal statutory rate and the effective rate is primarily due to a favorable mix of earnings in low tax jurisdictions and the favorable impact of a change in the Company’s prior estimates.
10
Note 5 - Earnings per Share
Basic earnings per share is based on the weighted-average number of common shares outstanding during the period. Diluted earnings per share is based on the number of shares used for the basic earnings per share calculation, adjusted for the dilutive effect of share options, restricted share equivalent (“RSE”) and performance restricted share equivalent (“PRSE”) awards.
| Three Months Ended March 31, | Six Months Ended March 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Basic weighted-average shares outstanding | |||||||||||||||||||||||
| Effect of dilutive securities: | |||||||||||||||||||||||
| Options, RSE and PRSE awards | |||||||||||||||||||||||
| Total dilutive securities | |||||||||||||||||||||||
| Diluted weighted-average shares outstanding | |||||||||||||||||||||||
For the three and six months ended March 31, 2023, the calculation of diluted weighted-average shares outstanding excludes 0.8 and 1.0, respectively, of share options and nil and 0.2, respectively, of RSE and PRSE awards because the effect of including these awards was anti-dilutive. For the three and six months ended March 31, 2022, the calculation of diluted weighted-average shares outstanding excludes 1.2 of share options for both periods and 0.1 and 0.4, respectively, of RSE and PRSE awards because the effect of including these awards was anti-dilutive.
Note 6 - Goodwill and Intangible Assets
| Wet Shave | Sun and Skin Care | Feminine Care | Total | ||||||||||||||||||||
| Gross balance as of October 1, 2022 | $ | $ | $ | $ | |||||||||||||||||||
| Accumulated goodwill impairment | ( | ( | ( | ||||||||||||||||||||
| Net balance as of October 1, 2022 | $ | $ | $ | $ | |||||||||||||||||||
| Changes in the six months ended March 31, 2023 | |||||||||||||||||||||||
| Cumulative translation adjustment | |||||||||||||||||||||||
| Gross balance as of March 31, 2023 | $ | $ | $ | $ | |||||||||||||||||||
| Accumulated goodwill impairment | ( | ( | ( | ||||||||||||||||||||
| Net balance as of March 31, 2023 | $ | $ | $ | $ | |||||||||||||||||||
| March 31, 2023 | September 30, 2022 | ||||||||||||||||||||||||||||||||||
| Carrying Amount | Accumulated Amortization | Net | Carrying Amount | Accumulated Amortization | Net | ||||||||||||||||||||||||||||||
| Indefinite lived | |||||||||||||||||||||||||||||||||||
| Trade names and brands | $ | $ | — | $ | $ | $ | — | $ | |||||||||||||||||||||||||||
| Amortizable | |||||||||||||||||||||||||||||||||||
| Trade names and brands | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||
| Technology and patents | |||||||||||||||||||||||||||||||||||
| Customer related and other | |||||||||||||||||||||||||||||||||||
| Amortizable intangible assets | |||||||||||||||||||||||||||||||||||
| Total intangible assets | $ | 1,280.9 | $ | 290.8 | $ | 990.1 | $ | 1,271.4 | $ | 274.7 | $ | 996.6 | |||||||||||||||||||||||
11
Amortization expense was $7.7 and $15.4 for the three and six months ended March 31, 2023, respectively, and $7.9 and $14.0 for the three and six months ended March 31, 2022, respectively. Estimated amortization expense for amortizable intangible assets for the remainder of fiscal 2023 and for fiscal 2024, 2025, 2026, 2027 and 2028 is $15.4 , $30.7 , $30.7 , $30.5 , $30.4 and $30.3 , respectively, and $227.5 thereafter.
Goodwill and intangible assets deemed to have an indefinite life are not amortized but are instead reviewed annually for impairment or when indicators of a potential impairment are present. The Company’s annual impairment testing date is July 1. An interim impairment analysis may indicate that carrying amounts of goodwill and other intangible assets require adjustment or that remaining useful lives should be revised. The Company determined there was no triggering event requiring an interim impairment analysis during the six months ended March 31, 2023.
Note 7 - Supplemental Balance Sheet Information
| March 31, 2023 | September 30, 2022 | ||||||||||
| Inventories | |||||||||||
| Raw materials and supplies | $ | $ | |||||||||
| Work in process | |||||||||||
| Finished products | |||||||||||
| Total inventories | $ | $ | |||||||||
| Other Current Assets | |||||||||||
| Prepaid expenses | |||||||||||
| Value added tax receivables | |||||||||||
| Income taxes receivable | |||||||||||
| Other | |||||||||||
| Total other current assets | $ | $ | |||||||||
| Property, Plant and Equipment | |||||||||||
| Land | $ | $ | |||||||||
| Buildings | |||||||||||
| Machinery and equipment | |||||||||||
| Capitalized software costs | |||||||||||
| Construction in progress | |||||||||||
| Total gross property, plant and equipment | |||||||||||
| Accumulated depreciation and amortization | ( | ( | |||||||||
| Total property, plant and equipment, net | $ | $ | |||||||||
| Other Current Liabilities | |||||||||||
| Accrued advertising and sales promotion | $ | $ | |||||||||
| Other | |||||||||||
| Total other current liabilities | $ | $ | |||||||||
| Other Liabilities | |||||||||||
| Pensions and other retirement benefits | $ | $ | |||||||||
| Other | |||||||||||
| Total other liabilities | $ | $ | |||||||||
12
Note 8 - Leases
The Company leases certain offices and manufacturing facilities, warehouses, employee vehicles and certain manufacturing related equipment and determines if an arrangement is or contains a lease at inception. Leases may include options to extend or terminate the lease, and those options are recorded on the Condensed Consolidated Balance Sheet when it is reasonably certain that the Company will exercise one of those options. All recorded leases are classified as operating leases, and lease expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheet.
A summary of the Company's lease information is as follows:
| March 31, 2023 | September 30, 2022 | |||||||||||||
| Assets | Classification | |||||||||||||
| Right of use assets | Other assets | $ | $ | |||||||||||
| Liabilities | ||||||||||||||
| Current lease liabilities | Other current liabilities | $ | $ | |||||||||||
| Long-term lease liabilities | Other liabilities | |||||||||||||
| Total lease liabilities | $ | $ | ||||||||||||
| Other information | ||||||||||||||
| Weighted-average remaining lease term (years) | ||||||||||||||
| Weighted-average incremental borrowing rate | % | % | ||||||||||||
| Three Months Ended March 31, | Six Months Ended March 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Statement of Earnings | |||||||||||||||||||||||
Lease expense (1) | $ | $ | $ | $ | |||||||||||||||||||
| Other information | |||||||||||||||||||||||
| Leased assets obtained in exchange for new lease liabilities | $ | $ | $ | $ | |||||||||||||||||||
| Cash paid for amounts included in the measurement of lease liabilities | $ | $ | $ | $ | |||||||||||||||||||
| Lease liability repayments | March 31, 2023 | ||||
| Remainder of fiscal 2023 | $ | ||||
| 2024 | |||||
| 2025 | |||||
| 2026 | |||||
| 2027 | |||||
| 2028 and thereafter | |||||
| Total future minimum lease commitments | |||||
| Less: Imputed interest | ( | ||||
| Present value of lease liabilities | $ | ||||
13
Note 9 - Accounts Receivable Facilities
The Company participates in accounts receivable facility programs both in the United States and Japan. These receivable agreements are between the Company and MUFG Bank, LTD, and the subsidiaries of both parties. Transfers under the accounts receivable repurchase agreements are accounted for as sales of accounts receivables, resulting in the receivables being derecognized from the Condensed Consolidated Balance Sheet. The purchaser assumes the credit risk at the time of sale and has the right at any time to assign, transfer, or participate any of its rights under the purchased receivables to another bank or financial institution. The purchase and sale of receivables under accounts receivable repurchase agreements is intended to be an absolute and irrevocable transfer without recourse by the purchaser to the Company for the creditworthiness of any obligor. The Company has considered its performance obligation to collect and service the receivables sold in the United States and Japan and has determined that such services are not material. The compensation received is considered acceptable servicing compensation and as such, the Company does not recognize a servicing asset or liability.
Accounts receivables sold were $315.5 and $527.6 for the three and six months ended March 31, 2023, respectively, and $282.0 and $437.2 for the three and six months ended March 31, 2022, respectively. The trade receivables sold that remained outstanding as of March 31, 2023 and September 30, 2022 were $141.1 and $78.7 , respectively. The net proceeds received were included in both Cash used by operating activities and Cash used by investing activities on the Condensed Consolidated Statements of Cash Flows. The difference between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of receivables in Other expense (income), net in the Condensed Consolidated Statements of Earnings and Comprehensive Income. The loss on sale of trade receivables was $1.5 and $2.4 for the three and six months ended March 31, 2023, respectively, and $0.3 and $0.5 for the three and six months ended March 31, 2022, respectively.
Note 10 - Debt
The detail of long-term debt was as follows:
| March 31, 2023 | September 30, 2022 | ||||||||||
| Senior notes, fixed interest rate of 5.500%, due 2028 | $ | $ | |||||||||
| Senior notes, fixed interest rate of 4.125%, due 2029 | |||||||||||
U.S. revolving credit facility (1) | |||||||||||
| Total long-term debt | |||||||||||
Less unamortized debt issuance costs and discount (2) | |||||||||||
| Total long-term debt | $ | $ | |||||||||
(1)The U.S. revolving credit facility matures in April 2025.
(2)As of March 31, 2023, the balance for the Senior Notes due 2028 and the Senior Notes due 2029 are reflected net of debt issuance costs of $7.6 and $4.8 , respectively. As of September 30, 2022, the balance for the Senior Notes due 2028 and the Senior Notes due 2029 are reflected net of debt issuance costs of $8.3 and $5.3 , respectively.
U.S. Revolving Credit Facility
On February 6, 2023, the Company amended its senior secured revolving credit facility in an aggregate principal amount of $425 dated March 28, 2020 to reflect the required transaction from the London Interbank Offered Rate (“LIBOR”) to the Secured Overnight Financing Rate (“SOFR”) as the dominant benchmark rate by June 30, 2023. The Company does not expect this change to have a material change on interest expense.
Note 11 - Retirement Plans
14
| Three Months Ended March 31, | Six Months Ended March 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Service cost | $ | $ | $ | $ | |||||||||||||||||||
| Interest cost | |||||||||||||||||||||||
| Expected return on plan assets | ( | ( | ( | ( | |||||||||||||||||||
| Recognized net actuarial loss | |||||||||||||||||||||||
| Defined benefit settlement loss | — | — | |||||||||||||||||||||
| Net periodic cost (income) | $ | $ | ( | $ | $ | ( | |||||||||||||||||
The service cost component of the net periodic cost (income) associated with the Company’s retirement plans is recorded to Cost of products sold and SG&A on the Condensed Consolidated Statement of Earnings and Comprehensive Income. The remaining net periodic cost (income) is recorded to Other expense (income), net on the Condensed Consolidated Statement of Earnings and Comprehensive Income.
The Company initiated the wind-up of its Canadian defined benefit pension plan (“Canada Plan”) in June 2021. On September 1, 2021, Edgewell Personal Care Canada ULC (“EPC Canada”) as administrator of the Canada Plan entered into a buy-in annuity purchase agreement (“Buy-in Agreement”) with Brookfield Annuity Company (“Brookfield Annuity”) for certain members of the Canada Plan. On January 25, 2023, the Company received approval by the Financial Services Regulatory Authority of Ontario to wind-up the Canada Plan. Upon regulatory approval of the Canada Plan, EPC Canada proceeded with purchasing annuities for the remaining Canada Plan participants and converting the Buy-in Agreement to a buy-out annuity purchase agreement (“Buy-out Agreement”), which was purchased and funded by the Canada Plan on March 31, 2023. The Company was relieved of its defined benefit pension obligation through its irrevocable commitment under the Buy-out Agreement. As of the settlement date, the Company remeasured its assets and its project benefit obligation associated with the Canada Plan. Upon settlement, the Company derecognized the assets, projected benefit obligation and losses remaining in accumulated other comprehensive loss associated with the Canada Plan, which resulted in a loss on settlement of $7.2. The loss was recorded in Other expense (income), net on the Condensed Consolidated Statement of Earnings and Comprehensive Income for the three and six months ended March 31, 2023.
Note 12 - Shareholders’ Equity
Share Repurchases
In January 2018, the Company’s Board of Directors (the “Board”) authorized the repurchase of up to 10.0 shares of the Company’s common stock, replacing the previous share repurchase authorization from May 2015. The Company repurchased 0.8 shares of its common stock for $30.0 during the six months ended March 31, 2023. There are 5.7 shares of common stock available for repurchase in the future under the Board’s authorization as of March 31, 2023. Any future share repurchases may be made in the open market, privately negotiated transactions, or otherwise permitted, and in such amounts and at such times as the Company deems appropriate based upon prevailing market conditions, business needs, and other factors.
Dividends
On November 3, 2022, the Board declared a quarterly cash dividend of $0.15 per common share for the fourth fiscal quarter of 2022. The dividend was paid on January 4, 2023 to shareholders of record as of the close of business on November 29, 2022.
On February 3, 2023, the Board declared a quarterly cash dividend of $0.15 per common share for the first fiscal quarter of 2023. The dividend was paid on April 5, 2023 to stockholders of record as of the close of business on March 8, 2023.
Dividends declared during the six months ended March 31, 2023 totaled $16.2 . Payments made for dividends during the six months ended March 31, 2023 totaled $16.1 .
15
Note 13 - Accumulated Other Comprehensive Loss
The following table presents the changes in accumulated other comprehensive loss (“AOCI”), net of tax, by component:
| Foreign Currency Translation Adjustments | Pension and Post-retirement Activity | Hedging Activity | Total | ||||||||||||||||||||
| Balance as of October 1, 2022 | $ | ( | $ | ( | $ | $ | ( | ||||||||||||||||
OCI before reclassifications (1) | ( | ( | |||||||||||||||||||||
| Reclassifications to earnings | ( | ||||||||||||||||||||||
| Balance as of March 31, 2023 | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
| Foreign Currency Translation Adjustments | Pension and Post-retirement Activity | Hedging Activity | Total | ||||||||||||||||||||
| Balance as of October 1, 2021 | $ | ( | $ | ( | $ | $ | ( | ||||||||||||||||
OCI before reclassifications (1) | ( | ( | ( | ||||||||||||||||||||
| Reclassifications to earnings | ( | ||||||||||||||||||||||
| Balance as of March 31, 2022 | $ | ( | $ | ( | $ | $ | ( | ||||||||||||||||
(1)OCI is defined as other comprehensive income (loss).
The following table presents the reclassifications out of AOCI:
| Three Months Ended March 31, | Six Months Ended March 31, | Affected Line Item in the Condensed Consolidated Statements of Earnings | ||||||||||||||||||||||||||||||
| Details of AOCI Components | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||||||||
| Gain / (Loss) on cash flow hedges | ||||||||||||||||||||||||||||||||
| Foreign exchange contracts | $ | $ | $ | $ | Other expense (income), net | |||||||||||||||||||||||||||
| Income tax expense (benefit) | Income tax provision | |||||||||||||||||||||||||||||||
| Amortization of defined benefit pension and postretirement items | ||||||||||||||||||||||||||||||||
Actuarial losses (1) | $ | ( | $ | ( | $ | ( | $ | ( | ||||||||||||||||||||||||
| Defined benefit settlement loss | ( | — | ( | — | Other expense (income), net | |||||||||||||||||||||||||||
| Income tax expense (benefit) | ( | ( | ( | ( | Income tax provision | |||||||||||||||||||||||||||
| ( | ( | ( | ( | |||||||||||||||||||||||||||||
| Total reclassifications for the period | $ | ( | $ | ( | $ | ( | $ | ( | ||||||||||||||||||||||||
(1)These AOCI components are included in the computation of net periodic cost. See Note 11 of Notes to Condensed Consolidated Financial Statements.
16
Note 14 - Financial Instruments and Risk Management
In the ordinary course of business, the Company may enter into contractual arrangements (also referred to as derivatives) to reduce its exposure to foreign currency. The Company has master netting agreements with all of its counterparties that allow for the settlement of contracts in an asset position with contracts in a liability position in the event of default. The Company manages counterparty risk through the utilization of investment grade commercial banks, diversification of counterparties, and its counterparty netting arrangements. The section below outlines the types of derivatives in place as of March 31, 2023 and September 30, 2022, as well as the Company’s objectives and strategies for holding derivative instruments.
Foreign Currency Risk
A significant share of the Company’s sales is tied to currencies other than the U.S. dollar, the Company’s reporting currency. As such, a weakening of currencies relative to the U.S. dollar can have a unfavorable impact on reported earnings. Conversely, strengthening of currencies relative to the U.S. dollar can improve reported results. The primary currencies to which the Company is exposed include the euro, the Japanese yen, the British pound, the Canadian dollar, and the Australian dollar.
Additionally, the Company’s foreign subsidiaries enter into internal and external transactions that create non-functional currency balance sheet positions at the foreign subsidiary level. These exposures are generally the result of intercompany purchases, intercompany loans and, to a lesser extent, external purchases, and are revalued in the foreign subsidiary’s local currency at the end of each month. Changes in the value of the non-functional currency balance sheet positions in relation to the foreign subsidiary’s local currency results in an exchange gain or loss recorded in Other expense (income), net. The primary currency to which the Company’s foreign subsidiaries are exposed is the U.S. dollar.
Cash Flow Hedges
As of March 31, 2023, the Company maintained a cash flow hedging program related to foreign currency risk. These derivative instruments have a high correlation to the underlying exposure being hedged and have been deemed highly effective by the Company for accounting purposes in offsetting the associated risk.
The Company has forward currency contracts to hedge cash flow uncertainty associated with currency fluctuations. These transactions are accounted for as cash flow hedges. The Company had unrealized pre-tax losses of $0.3 and gains of $11.3 as of March 31, 2023 and September 30, 2022, respectively, on these forward currency contracts, which are accounted for as cash flow hedges and included in AOCI. Assuming foreign exchange rates versus the U.S. dollar remain at March 31, 2023 levels over the next 12 months, the majority of the pre-tax loss included in AOCI as of March 31, 2023 is expected to be included in Other expense (income), net. Contract maturities for these hedges extend into fiscal 2024. As of March 31, 2023, there were 64 open foreign currency contracts with a total notional value of $114.1 .
Derivatives not Designated as Hedges
The Company has foreign currency derivative contracts, which are not designated as cash flow hedges for accounting purposes, to hedge balance sheet exposures. Any gains or losses on these contracts are expected to be offset by exchange gains or losses on the underlying exposures and, thus, are not expected to be subject to significant market risk. The change in the estimated fair value of the foreign currency contracts for the three and six months ended March 31, 2023, resulted in a gain of $ and a loss of $, respectively, compared to a gain of $ and $ for the three and six months ended March 31 2022, respectively, and was recorded in Other expense (income), net in the Condensed Consolidated Statements of Earnings and Comprehensive Income. As of March 31, 2023, there were eight open foreign currency derivative contracts not designated as cash flow hedges with a total notional value of $69.9 .
The following table provides estimated fair values of derivative instruments:
Fair Value of Assets (Liabilities) as of (1) | |||||||||||
| March 31, 2023 | September 30, 2022 | ||||||||||
| Derivatives designated as cash flow hedging relationships: | |||||||||||
| Foreign currency contracts | $ | ( | $ | ||||||||
| Derivatives not designated as cash flow hedging relationships: | |||||||||||
| Foreign currency contracts | $ | ( | $ | ||||||||
(1)Derivative assets are presented in Other current assets or Other assets. Derivative liabilities are presented in Other current liabilities or Other liabilities.
17
The following table provides the pre-tax amounts of gains and losses on derivative instruments:
| Three Months Ended March 31, | Six Months Ended March 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Derivatives designated as cash flow hedging relationships: | |||||||||||||||||||||||
| Foreign currency contracts | |||||||||||||||||||||||
Gain (loss) recognized in OCI (1) | $ | $ | $ | ( | $ | ||||||||||||||||||
Gain reclassified from AOCI into income (1) (2) | |||||||||||||||||||||||
| Derivatives not designated as cash flow hedging relationships: | |||||||||||||||||||||||
| Foreign currency contracts | |||||||||||||||||||||||
Gain (loss) recognized in income (2) | $ | $ | $ | $ | |||||||||||||||||||
(1)Each of these derivative instruments had a high correlation to the underlying exposure being hedged for the periods indicated and have been deemed highly effective by the Company in offsetting associated risk.
The following table provides financial assets and liabilities for balance sheet offsetting:
| As of March 31, 2023 | As of September 30, 2022 | ||||||||||||||||||||||
Assets (1) | Liabilities (2) | Assets (1) | Liabilities (2) | ||||||||||||||||||||
| Foreign currency contracts | |||||||||||||||||||||||
| Gross amounts of recognized assets (liabilities) | $ | $ | ( | $ | $ | ( | |||||||||||||||||
| Gross amounts offset in the balance sheet | ( | ||||||||||||||||||||||
| Net amounts of assets (liabilities) presented in the balance sheet | $ | $ | ( | $ | $ | ( | |||||||||||||||||
(1)All derivative assets are presented in Other current assets or Other assets.
(2)All derivative liabilities are presented in Other current liabilities or Other liabilities.
Fair Value Hierarchy
Accounting guidance on fair value measurements for certain financial assets and liabilities requires that assets and liabilities carried at fair value be classified in one of the following three categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions or external inputs from inactive markets.
| March 31, 2023 | September 30, 2022 | ||||||||||
| Assets (Liabilities) at estimated fair value: | |||||||||||
| Deferred compensation liability | $ | ( | $ | ( | |||||||
| Derivatives - foreign currency contracts (liability) asset | ( | ||||||||||
| Net liabilities at estimated fair value | $ | ( | $ | ( | |||||||
The estimated fair value of the deferred compensation liability is determined based upon the quoted market prices of the investment options that are offered under the plan. As of March 31, 2023 and September 30, 2022, the estimated fair value of foreign currency contracts is the amount that the Company would receive or pay to terminate the contracts, considering first the quoted market prices of comparable agreements or, in the absence of quoted market prices, factors such as interest rates, currency exchange rates, and remaining maturities.
As of March 31, 2023 and September 30, 2022, the Company had no Level 1 financial assets or liabilities, other than pension plan assets, and no Level 3 financial assets or liabilities as of March 31, 2023 and September 30, 2022, respectively.
18
Note 15 - Segment Data
For an overview of the Company’s segments, refer to Note 1 of the Notes to Condensed Consolidated Financial Statements. Segment performance is evaluated based on segment profit, excluding certain U.S. GAAP items that management does not believe are indicative of ongoing operating performance. These items include general corporate expenses, share-based compensation costs, amortization of intangible assets and certain other items, including restructuring charges, acquisition and integration costs, Sun Care reformulation costs, value-added tax settlement costs, loss on defined benefit settlement and at times management excludes other costs. Financial items, such as interest income and expense, are managed on a global basis at the corporate level and therefore are excluded from segment profit. The exclusion of such charges from segment results reflects management’s view on how management monitors and evaluates segment operating performance, generates future operating plans and makes strategic decisions regarding the allocation of capital.
The Company’s operating model includes some shared business functions across the segments, including product warehousing and distribution, transaction processing functions and, in most cases, combined sales force and management teams. The Company applies a fully allocated cost basis in which shared business functions are allocated between the segments.
Segment net sales and profitability are presented below:
| Three Months Ended March 31, | Six Months Ended March 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Net Sales | |||||||||||||||||||||||
| Wet Shave | $ | $ | $ | $ | |||||||||||||||||||
| Sun and Skin Care | |||||||||||||||||||||||
| Feminine Care | |||||||||||||||||||||||
| Total net sales | $ | $ | $ | $ | |||||||||||||||||||
| Segment Profit | |||||||||||||||||||||||
| Wet Shave | $ | $ | $ | $ | |||||||||||||||||||
| Sun and Skin Care | |||||||||||||||||||||||
| Feminine Care | |||||||||||||||||||||||
| Total segment profit | |||||||||||||||||||||||
| General corporate and other expenses | ( | ( | ( | ( | |||||||||||||||||||
| Amortization of intangibles | ( | ( | ( | ( | |||||||||||||||||||
| Interest and other expense, net | ( | ( | ( | ( | |||||||||||||||||||
Restructuring and related costs (1) | ( | ( | ( | ( | |||||||||||||||||||
Acquisition and integration costs (2) | ( | ( | ( | ( | |||||||||||||||||||
Sun Care reformulation costs (3) | ( | ( | ( | ( | |||||||||||||||||||
Defined benefit settlement loss (4) | ( | ( | |||||||||||||||||||||
VAT settlement costs (5) | ( | ||||||||||||||||||||||
| Other costs | ( | — | ( | — | |||||||||||||||||||
| Total earnings before income taxes | $ | $ | $ | $ | |||||||||||||||||||
(1)Restructuring costs of $0.2 are included within Cost of products sold for the three and six months ended March 31, 2023. Includes pre-tax SG&A of $0.1 for the six months ended March 31, 2023 and $0.2 for both the three and six months ended March 31, 2022.
19
(2)Includes pre-tax SG&A of $0.6 and $6.3 for the three and six months ended March 31, 2022, respectively, for the Acquisition. Additionally, includes Cost of Products Sold of $0.5 and $0.8 related to the valuation of acquired inventory for the Acquisition for the three and six months ended March 31, 2022, respectively. See Note 2 of the Notes to Condensed Consolidated Financial Statements.
(3)Includes pre-tax R&D of $0.6 and $1.1 for the three and six months ended March 31, 2023, respectively, and pre-tax Cost of Products Sold of $0.2 and $3.5 for the three and six months ended March 31, 2022, respectively, related to the reformulation, recall and destruction of certain Sun Care products.
(4)Includes pre-tax loss of $7.2 for the three and six months ended March 31, 2023 related the settlement of the Canada Plan. See Note 11 of the Notes to Condensed Consolidated Financial Statements.
(5)Includes pre-tax SG&A of $3.4 for the six months ended March 31, 2022 related to the estimated settlement of a prior years’ value-added tax audit of the Company’s German subsidiary.
| Three Months Ended March 31, | Six Months Ended March 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Net Sales to Customers | |||||||||||||||||||||||
| United States | $ | $ | $ | $ | |||||||||||||||||||
| International | |||||||||||||||||||||||
| Total net sales | $ | $ | $ | $ | |||||||||||||||||||
| Three Months Ended March 31, | Six Months Ended March 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Razors and blades | $ | $ | $ | $ | |||||||||||||||||||
| Tampons, pads, and liners | |||||||||||||||||||||||
| Sun care products | |||||||||||||||||||||||
| Grooming products | |||||||||||||||||||||||
| Wipes and other skin care | |||||||||||||||||||||||
| Shaving gels and creams | |||||||||||||||||||||||
| Total net sales | $ | $ | $ | $ | |||||||||||||||||||
Note 16 - Commitments and Contingencies
Legal Proceedings
The Company and its subsidiaries are subject to a number of legal proceedings in various jurisdictions arising out of its operations during the ordinary course of business. Many of these legal matters are in preliminary stages and involve complex issues of law and fact and may proceed for protracted periods of time. The amount of liability, if any, from these proceedings cannot be determined with certainty. The Company reviews its legal proceedings and claims, regulatory reviews and inspections and other legal proceedings on an ongoing basis and follows appropriate accounting guidance when making accrual and disclosure decisions. The Company establishes accruals for those contingencies when the incurrence of a loss is probable and can be reasonably estimated and discloses the amount accrued and the amount of a reasonably possible loss in excess of the amount accrued if such disclosure is necessary for its financial statements to not be misleading. The Company does not record liabilities when the likelihood that the liability has been incurred is probable, but the amount cannot be reasonably estimated. Based upon present information, the Company believes that its liability, if any, arising from such pending legal proceedings, asserted legal claims, and known potential legal claims which are likely to be asserted, is not reasonably likely to be material to its financial position, results of operations or cash flows, when taking into account established accruals for estimated liabilities.
20
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
(Amounts in millions, except per share data, unaudited)
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited Condensed Consolidated Financial Statements and the accompanying notes included in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K filed with the SEC on November 16, 2022 (the “2022 Annual Report”). The following discussion may contain forward-looking statements that reflect our plans, estimates, and beliefs and involve risks, uncertainties, and assumptions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed within “Forward-Looking Statements” below and in Item 1A. Risk Factors and “Forward-Looking Statements” included within our 2022 Annual Report.
Forward-Looking Statements
This document contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of Edgewell Personal Care Company or any of our businesses (the “Company”). Forward-looking statements generally can be identified by the use of words or phrases such as “believe,” “expect,” “expectation,” “anticipate,” “may,” “could,” “intend,” “estimate,” “plan,” “target,” “predict,” “likely,” “will,” “should,” “forecast,” “outlook,” “strategy,” or other similar words or phrases. These statements are not based on historical facts, but instead reflect our expectations, estimates or projections concerning future results or events, including, without limitation, the future earnings and performance of Edgewell Personal Care Company or any of our businesses. Many factors outside our control could affect the realization of these estimates. These statements are not guarantees of performance and are inherently subject to known and unknown risks, uncertainties and assumptions that are difficult to predict and could cause our actual results to differ materially from those indicated by those statements. We cannot assure you that any of our expectations, estimates or projections will be achieved. The forward-looking statements included in this report are only made as of the date of this report, and we disclaim any obligation to publicly update any forward-looking statement to reflect subsequent events or circumstances, except as required by law. You should not place undue reliance on these statements.
In addition, other risks and uncertainties not presently known to us or that we presently consider immaterial could significantly affect the forward-looking statements. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. Risks and uncertainties include those detailed from time to time in our publicly filed documents, including in Item 1A. Risk Factors of Part I of our 2022 Annual Report.
Non-GAAP Financial Measures
While we report financial results in accordance with GAAP, this discussion also includes non-GAAP measures. These non-GAAP measures are referred to as “adjusted” or “organic” and exclude items such as restructuring costs, acquisition and integration costs, and other non-standard items. Reconciliations of non-GAAP measures are included within this Management’s Discussion and Analysis of Financial Condition and Results of Operations.
This non-GAAP information is provided as a supplement to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. We use this non-GAAP information internally to make operating decisions and believe it is helpful to investors because it allows more meaningful period-to-period comparisons of ongoing operating results. Given certain significant events, including the acquisition of Billie, Inc. (“Billie”) (the “Acquisition”) on November 29, 2021, we view the use of non-GAAP measures that take into account the impact of these unique events as particularly valuable in understanding our underlying operational results and providing insights into future performance. The information can also be used to perform trend analysis and to better identify operating trends that may otherwise be masked or distorted by the types of items that are excluded. This non-GAAP information is also a component in determining management’s incentive compensation. Finally, we believe this information provides more transparency.
The following provides additional detail on our non-GAAP measures for the periods presented:
•We analyze net sales and segment profit on an organic basis to better measure the comparability of results between periods. Organic net sales and organic segment profit exclude the impact of changes in foreign currency translation and the impact of acquisitions.
◦Organic net sales will be unfavorably impacted in October and November of fiscal 2023 by the Billie acquisition as sales that were previously reported as third party sales to Billie are now included as inter-company sales.
◦Segment profit will be impacted by fluctuations in translation and transactional foreign currency. The impact of currency was applied to segments using management’s best estimate.
21
•Additionally, we utilize “adjusted” non-GAAP measures including adjusted gross profit, adjusted selling general administrative (“SG&A”), adjusted operating income, adjusted income taxes, adjusted net earnings, and adjusted diluted earnings per share internally to make operating decisions. The following items are excluded when analyzing non-GAAP measures: restructuring and related costs, acquisition and integration costs, Sun Care reformulation charges, value-added tax (“VAT”) settlement costs, loss on defined benefit settlement and other costs.
All comparisons are with the same period in the prior year, unless otherwise noted.
Industry and Market Data
Unless we indicate otherwise, we base the information contained or incorporated by reference herein, concerning our industry on our general knowledge and expectations. Our market position, market share, and industry market size are estimates based on internal and external data from various industry analyses, our internal research and adjustments, and assumptions that we believe to be reasonable. We have not independently verified data from industry analyses and cannot guarantee its accuracy or completeness. In addition, we believe that industry, market size, market position and market share data within our industry provides general guidance but is inherently imprecise and has not been verified by any independent source. Further, our estimates and assumptions involve risks and uncertainties and are subject to change based on various factors, including those discussed in Item 1A. Risk Factors in Part I of our 2022 Annual Report. These and other factors could cause results to differ materially from those expressed in the estimates and assumptions. You are cautioned not to place undue reliance on this data.
Retail sales for purposes of market size, market position and market share information are based on retail sales in U.S. dollars.
Trademarks and Trade Names
We own or have rights to use trademarks and trade names that we use in conjunction with the operation of our business, which appear throughout this Quarterly Report on Form 10-Q. We may also refer to brand names, trademarks, service marks and trade names of other companies and organizations, which are the property of their respective owners.
Impact of the COVID-19 Pandemic
Throughout the novel coronavirus 2019 (“COVID-19”) pandemic, we have taken and continue to take significant measures to protect our employees and businesses, while remaining in compliance with local, state and national guidelines.
To date, we have not experienced any material operational disruptions across our manufacturing or distribution facilities. However, due to the uncertainty resulting from COVID-19, the impact and timing of additional unforeseen disruptions cannot be reasonably estimated at this time.
We will continue to monitor for any future material developments regarding COVD-19, if any, and related responses of local, state and national governments and our consumers suppliers and employees.
Significant Events
Acquisitions
On November 29, 2021, we completed the Acquisition, for a purchase price of $309.4, net of cash acquired, utilizing a combination of cash on hand and by drawing on that certain U.S. revolving credit facility due 2025 between the Company and Bank of America, N.A., as administrative agent, and lenders parties thereto (the “Revolving Credit Facility”). As a result, Billie became a wholly owned subsidiary of the Company. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for further discussion.
22
Executive Summary
The following is a summary of key results for the second quarter and first six months of fiscal 2023, as compared to the corresponding periods in fiscal 2022. Net earnings and earnings per share (“EPS”) for the periods presented were impacted by restructuring and related costs, acquisition and integration costs, Sun Care reformulation costs, VAT settlement costs, loss on defined benefit settlement and other costs, as described in the table below. The impact of these items on reported net earnings and EPS are provided as a reconciliation of net earnings and EPS to adjusted net earnings and adjusted diluted EPS, both of which are non-GAAP measures.
Second Quarter of Fiscal 2023
•Net sales in the second quarter of fiscal 2023 increased 9.3% as compared to the prior year quarter to $598.4. Organic net sales increased 11.4% compared to the prior year quarter, with growth in all segments and major geographic regions, as international markets increased 13.2 % and North America markets increased 10.5%. In aggregate, growth in organic net sales was driven largely in equal parts by increased pricing and volumes.
•Net earnings in the second quarter of fiscal 2023 were $19.0 compared to $23.2 in the prior year quarter. On an adjusted basis, net earnings for the second quarter of fiscal 2023 were $29.0 compared to $27.0 in the prior year quarter. Adjusted net earnings increased primarily due to higher sales and gross profit.
•Net earnings per diluted share during the second quarter of fiscal 2023 were $0.37 compared to $0.43 in the prior year quarter. On an adjusted basis, net earnings per diluted share during the second quarter of fiscal 2023 were $0.56 compared to $0.50 in the prior year quarter.
| Three Months Ended March 31, 2023 | |||||||||||||||||||||||||||||||||||||||||
| Gross Profit | SG&A | Operating Income | EBIT(1) | Income taxes | Net Earnings | Diluted EPS | |||||||||||||||||||||||||||||||||||
| GAAP — Reported | $ | 241.7 | $ | 105.2 | $ | 56.2 | $ | 26.0 | $ | 7.0 | $ | 19.0 | $ | 0.37 | |||||||||||||||||||||||||||
| Restructuring and related costs | 0.2 | — | 3.2 | 3.2 | 0.9 | 2.3 | 0.04 | ||||||||||||||||||||||||||||||||||
| Acquisition and integration costs | — | 2.0 | 2.0 | 2.0 | 0.5 | 1.5 | 0.03 | ||||||||||||||||||||||||||||||||||
| Defined benefit settlement loss | — | — | — | 7.2 | 1.9 | 5.3 | 0.10 | ||||||||||||||||||||||||||||||||||
| Sun Care reformulation costs | — | — | 0.6 | 0.6 | 0.1 | 0.5 | 0.01 | ||||||||||||||||||||||||||||||||||
| Other Costs | — | 0.5 | 0.5 | 0.5 | 0.1 | 0.4 | 0.01 | ||||||||||||||||||||||||||||||||||
| Total Adjusted Non-GAAP | $ | 241.9 | $ | 102.7 | $ | 62.5 | $ | 39.5 | $ | 10.5 | $ | 29.0 | $ | 0.56 | |||||||||||||||||||||||||||
| GAAP as a percent of net sales | 40.4 | % | 17.6 | % | 9.4 | % | GAAP effective tax rate | 26.9 | % | ||||||||||||||||||||||||||||||||
| Adjusted as a percent of net sales | 40.4 | % | 17.2 | % | 10.4 | % | Adjusted effective tax rate | 26.5 | % | ||||||||||||||||||||||||||||||||
| Three Months Ended March 31, 2022 | |||||||||||||||||||||||||||||||||||||||||
| Gross Profit | SG&A | Operating Income | EBIT(1) | Income taxes | Net Earnings | Diluted EPS | |||||||||||||||||||||||||||||||||||
| GAAP — Reported | $ | 230.1 | $ | 101.3 | $ | 41.7 | $ | 27.1 | $ | 3.9 | $ | 23.2 | $ | 0.43 | |||||||||||||||||||||||||||
| Restructuring and related costs | — | 0.2 | 3.7 | 3.7 | 1.0 | 2.7 | 0.05 | ||||||||||||||||||||||||||||||||||
| Acquisition and integration costs | 0.5 | 0.6 | 1.1 | 1.1 | 0.2 | 0.9 | 0.02 | ||||||||||||||||||||||||||||||||||
| Sun Care reformulation costs | 0.2 | — | 0.2 | 0.2 | — | 0.2 | — | ||||||||||||||||||||||||||||||||||
| Total Adjusted Non-GAAP | $ | 230.8 | $ | 100.5 | $ | 46.7 | $ | 32.1 | $ | 5.1 | $ | 27.0 | $ | 0.50 | |||||||||||||||||||||||||||
| GAAP as a percent of net sales | 42.0 | % | 18.5 | % | 7.6 | % | GAAP effective tax rate | 14.4 | % | ||||||||||||||||||||||||||||||||
| Adjusted as a percent of net sales | 42.1 | % | 18.3 | % | 8.5 | % | Adjusted effective tax rate | 16.0 | % | ||||||||||||||||||||||||||||||||
(1)EBIT is defined as Earnings before Income taxes.
First Six Months of Fiscal 2023
•Net sales for the first six months of fiscal 2023 increased 5.6% to $1,067.5. Organic net sales increased 7.6% compared to the prior year period, with strong Sun Care and Grooming sales globally, and strong sales in North America for Men’s Shave and Feminine Care.
23
•Net earnings for the first six months of fiscal 2023 were $30.9 compared to $34.4 in the prior year period. On an adjusted basis, net earnings for the first six months of fiscal 2023 were $45.0 compared to $50.2 in the prior year period. Adjusted net earnings declined despite higher net sales, due the impact of higher input costs, foreign currency and interest costs.
•Net earnings per diluted share during the first six months of fiscal 2023 were $0.60 compared to $0.63 in the prior year period. On an adjusted basis, net earnings per diluted share during the first six months of fiscal 2023 were $0.87 compared to $0.92 in the prior year period.
| Six Months Ended March 31, 2023 | |||||||||||||||||||||||||||||||||||||||||
| Gross Profit | SG&A | Operating Income | EBIT(1) | Income taxes | Net Earnings | Diluted EPS | |||||||||||||||||||||||||||||||||||
| GAAP — Reported | $ | 430.7 | $ | 200.9 | $ | 87.5 | $ | 42.4 | $ | 11.5 | $ | 30.9 | $ | 0.60 | |||||||||||||||||||||||||||
| Restructuring and related costs | 0.2 | 0.1 | 6.0 | 6.0 | 1.6 | 4.4 | 0.08 | ||||||||||||||||||||||||||||||||||
| Acquisition and integration costs | — | 4.1 | 4.1 | 4.1 | 1.0 | 3.1 | 0.06 | ||||||||||||||||||||||||||||||||||
| Defined benefit settlement loss | — | — | — | 7.2 | 1.9 | 5.3 | 0.10 | ||||||||||||||||||||||||||||||||||
| Sun Care reformulation costs | — | — | 1.1 | 1.1 | 0.2 | 0.9 | 0.02 | ||||||||||||||||||||||||||||||||||
| Other Costs | — | 0.5 | 0.5 | 0.5 | 0.1 | 0.4 | 0.01 | ||||||||||||||||||||||||||||||||||
| Total Adjusted Non-GAAP | $ | 430.9 | $ | 196.2 | $ | 99.2 | $ | 61.3 | $ | 16.3 | $ | 45.0 | $ | 0.87 | |||||||||||||||||||||||||||
| GAAP as a percent of net sales | 40.3 | % | 18.8 | % | 8.2 | % | GAAP effective tax rate | 27.0 | % | ||||||||||||||||||||||||||||||||
| Adjusted as a percent of net sales | 40.4 | % | 18.4 | % | 9.3 | % | Adjusted effective tax rate | 26.6 | % | ||||||||||||||||||||||||||||||||
| Six Months Ended March 31, 2022 | |||||||||||||||||||||||||||||||||||||||||
| Gross Profit | SG&A | Operating Income | EBIT(1) | Income taxes | Net Earnings | Diluted EPS | |||||||||||||||||||||||||||||||||||
| GAAP — Reported | $ | 420.0 | $ | 198.2 | $ | 73.5 | $ | 43.3 | $ | 8.9 | $ | 34.4 | $ | 0.63 | |||||||||||||||||||||||||||
| Restructuring and related costs | — | 0.2 | 5.9 | 5.9 | 1.6 | 4.3 | 0.08 | ||||||||||||||||||||||||||||||||||
| Acquisition and integration costs | 0.8 | 6.3 | 7.1 | 7.1 | 0.5 | 6.6 | 0.12 | ||||||||||||||||||||||||||||||||||
| Value-added tax settlement costs | — | 3.4 | 3.4 | 3.4 | 1.1 | 2.3 | 0.04 | ||||||||||||||||||||||||||||||||||
| Sun Care reformulation costs | 3.5 | — | 3.5 | 3.5 | 0.9 | 2.6 | 0.05 | ||||||||||||||||||||||||||||||||||
| Total Adjusted Non-GAAP | $ | 424.3 | $ | 188.3 | $ | 93.4 | $ | 63.2 | $ | 13.0 | $ | 50.2 | $ | 0.92 | |||||||||||||||||||||||||||
| GAAP as a percent of net sales | 41.5 | % | 19.6 | % | 7.3 | % | GAAP effective tax rate | 20.5 | % | ||||||||||||||||||||||||||||||||
| Adjusted as a percent of net sales | 42.0 | % | 18.6 | % | 9.2 | % | Adjusted effective tax rate | 20.5 | % | ||||||||||||||||||||||||||||||||
(1)EBIT is defined as Earnings before Income taxes.
Operating Results
The following table presents changes in net sales for the second quarter and first six months of fiscal 2023, as compared to the corresponding periods in fiscal 2022, and provides a reconciliation of organic net sales to reported amounts.
24
Net Sales
| Net Sales - Total Company | |||||||||||||||||||||||
| Period Ended March 31, 2023 | |||||||||||||||||||||||
| Q2 | % Chg | Six Months | % Chg | ||||||||||||||||||||
| Net sales - fiscal 2022 | $ | 547.7 | $ | 1,011.0 | |||||||||||||||||||
| Organic | 62.5 | 11.4 | % | 76.5 | 7.6 | % | |||||||||||||||||
| Impact of Billie acquisition, net | — | — | % | 12.0 | 1.2 | % | |||||||||||||||||
| Impact of currency | (11.8) | (2.1) | % | (32.0) | (3.2) | % | |||||||||||||||||
| Net sales - fiscal 2023 | $ | 598.4 | 9.3 | % | $ | 1,067.5 | 5.6 | % | |||||||||||||||
For the second quarter of fiscal 2023, net sales were $598.4, an increase of 9.3%, including a $11.8, or 2.1% unfavorable impact from currency movements. Organic net sales increased 11.4%, with growth in all segments and major geographic regions, as international markets increased 13.2% and North America markets increased 10.5%.In aggregate, growth in organic net sales was driven largely in equal parts by increased pricing and volumes.
For the first six months of fiscal 2023, net sales were $1,067.5, an increase of 5.6%, including a $12.0, or 1.2% increase from the Acquisition and a $32.0 or 3.2% decrease due to unfavorable impact from currency movements. Organic net sales increased 7.6% driven by favorable pricing and volumes for Sun Care and Feminine Care and favorable pricing for Wet Shave.
For further discussion regarding net sales, including a summary of reported versus organic changes, see “Segment Results.”
Gross Profit
Gross profit was $241.7 during the second quarter of fiscal 2023, including a $10.6 unfavorable impact from currency movements, compared to $230.1 in the prior year quarter. Gross margin as a percent of net sales for the second quarter of fiscal 2023 was 40.4% compared to 42.0% in the prior year quarter. Adjusted gross margin percentage decreased 170-basis points as gross inflationary pressures of approximately 550-basis points was mostly offset by approximately 220-basis points of productivity savings and a 285-basis points benefit from higher pricing and promotion management.
Gross profit was $430.7 during the first six months of fiscal 2023, compared to $420.0 in the prior year period. Gross margin as a percent of net sales for the first six months of fiscal 2023 was 40.3% compared to 41.5% in the prior year period. Adjusted gross margin percentage decreased by 160-basis points, driven by higher commodity costs and the impact of inflation, and was partially offset by productivity savings and the benefits from higher pricing and promotion management.
Selling, General and Administrative Expense
SG&A was $105.2 in the second quarter of fiscal 2023, or 17.6% of net sales, compared to $101.3 in the prior year quarter, or 18.5% of net sales. Adjusted SG&A as a percent of net sales was 17.2%, a decrease of 110-basis points, as improved leverage, the benefits of operational efficiency programs and favorable impact from currency movements more than offset the impact of higher people costs and travel expense.
SG&A was $200.9 in the first six months of fiscal 2023, or 18.8% of net sales, compared to $198.2 in the prior year period, or 19.6% of net sales. Adjusted SG&A as a percent of net sales was 18.4%, a decline of 20-basis points, as the benefits of operational efficiency programs and favorable impact from currency movements more than offset the impact of higher people costs and additional costs associated with the Acquisition, including amortization expense.
Advertising and Sales Promotion Expense
For the second quarter of fiscal 2023, advertising and promotion expense (“A&P”) was $62.9, a decrease of $7.0 compared to $69.9 in the prior year quarter. A&P as a percent of net sales was 10.5%, as compared to 12.8% in the prior year quarter, primarily due to timing of brand investments and marketing campaigns.
For the first six months of fiscal 2023, A&P was $108.8, a decrease of $7.3, compared to the prior year period. A&P as a percent of net sales was 10.2%, compared to 11.5% in the prior year period. The decrease in A&P was primarily due to lower media spend and agency fees offset by higher investment in Wet Shave.
Research and Development Expense
Research and development expense (“R&D”) for the second quarter of fiscal 2023 was $14.4, compared to $13.7 in the prior year quarter. As a percent of net sales, R&D was 2.4% in the second quarter of fiscal 2023 compared to 2.5% in the prior year quarter. R&D for the first six months of fiscal 2023 was $27.8, compared to $26.5 in the prior year period. As a percent of net sales, R&D was 2.6% in the first six months of fiscal 2023 as well as 2.6% in the prior year period.
25
Interest Expense Associated with Debt
Interest expense associated with debt for the second quarter of fiscal 2023 was $20.7, compared to $18.0 in the prior year quarter. For the first six months of fiscal 2023, interest expense was $40.6 compared to $35.3 in the prior year period. The increase in interest expense was the result of higher interest rates and a higher overall debt balance on the Company’s Revolving Credit Facility.
Other expense (income), net
Other expense (income), net was $9.5 of expense in the second quarter of fiscal 2023, compared to $3.4 of income in the prior year quarter. Other expense (income), net was $4.5 of expense during the first six months of fiscal 2023, compared to $5.1 of income during the prior year period. The second quarter and first six months of 2023 include the loss on the settlement of the Canadian Plan of $7.2.
Income Tax Provision
The effective tax rate for the three and six months ended March 31, 2023 was 26.9% and 27.0%, respectively, compared to 14.4% and 20.5% in the prior year period. The fiscal 2023 effective tax rate reflects the unfavorable mix of earnings in higher tax rate jurisdictions. On an adjusted basis, the effective tax rate was 26.5% and 26.6% for the three and six months ended March 31, 2023 and 16.0% and 20.5% for the three and six months ended March 31, 2022, respectively.
Operating Model Redesign
In fiscal 2023, the Company is continuing to strengthen its operating model, simplify the organization and improve manufacturing and supply chain efficiency. As a result of these actions, we expect to incur charges of approximately $19 in fiscal 2023. We incurred $3.2 and $6.0 during the second quarter and first six months of fiscal 2023, respectively, primarily related to employee severance and benefit costs.
Segment Results
The following tables present changes in segment net sales and segment profit for the second quarter and first six months of fiscal 2023, compared to the corresponding periods in fiscal 2022, and provide a reconciliation of organic segment net sales and organic segment profit to reported amounts. For a reconciliation of segment profit to Earnings before income taxes, refer to Note 15 of Notes to Condensed Consolidated Financial Statements.
Our operating model includes some shared business functions across segments, including product warehousing and distribution, transaction processing functions and, in most cases, a combined sales force and management teams. We apply a fully allocated cost basis in which shared business functions are allocated between segments.
Wet Shave
| Net Sales - Wet Shave | |||||||||||||||||||||||
| Period Ended March 31, 2023 | |||||||||||||||||||||||
| Q2 | % Chg | Six Months | % Chg | ||||||||||||||||||||
| Net sales - fiscal 2022 | $ | 305.0 | $ | 591.1 | |||||||||||||||||||
| Organic | 14.0 | 4.6 | % | 8.3 | 1.4 | % | |||||||||||||||||
| Impact of Billie acquisition, net | — | — | % | 12.0 | 2.0 | % | |||||||||||||||||
| Impact of currency | (10.4) | (3.4) | % | (27.5) | (4.8) | % | |||||||||||||||||
| Net sales - fiscal 2023 | $ | 308.6 | 1.2 | % | $ | 583.9 | (1.4) | % | |||||||||||||||
Wet Shave net sales for the second quarter of fiscal 2023 increased $3.6, or 1.2%. Organic net sales increased $14.0, or 4.6%, primarily driven by balanced growth in both North America and international markets, driven largely by increased pricing, as volumes were essentially flat. Growth in Men’s Systems, Disposable’s and Shave Preps was partly offset by declines in Women’s Systems in North America.
Wet Shave net sales for the first six months of fiscal 2023 decreased $7.2, or 1.4% as compared to the prior year period. Organic net sales increase of $8.3, million was primarily driven by growth in International Women’s systems. Organic growth was more than offset by the unfavorable impact of currency movements.
26
| Segment Profit - Wet Shave | |||||||||||||||||||||||
| Period Ended March 31, 2023 | |||||||||||||||||||||||
| Q2 | % Chg | Six Months | % Chg | ||||||||||||||||||||
| Segment profit - fiscal 2022 | $ | 27.6 | $ | 79.1 | |||||||||||||||||||
| Organic | 14.6 | 52.9 | % | 6.4 | 8.1 | % | |||||||||||||||||
| Impact of currency | (7.1) | (25.8) | % | (15.0) | (19.0) | % | |||||||||||||||||
| Segment profit - fiscal 2023 | $ | 35.1 | 27.1 | % | $ | 70.5 | (10.9) | % | |||||||||||||||
Wet Shave segment profit for the second quarter of fiscal 2023 was $35.1, an increase of $7.5, or 27.1%. The increase in segment profit was reflective of higher organic net sales and gross profit as well as lower marketing expense.
Wet Shave segment profit for the first six months of fiscal 2023 was $70.5, a decrease of $8.6, or 10.9%. Organic segment profit increased $6.4, or 8.1%, primarily driven by growth in both North American and International markets.
Sun and Skin Care
| Net Sales - Sun and Skin Care | |||||||||||||||||||||||
| Period Ended March 31, 2023 | |||||||||||||||||||||||
| Q2 | % Chg | Six Months | % Chg | ||||||||||||||||||||
| Net sales - fiscal 2022 | $ | 183.3 | $ | 288.1 | |||||||||||||||||||
| Organic | 27.5 | 15.0 | % | 38.5 | 13.4 | % | |||||||||||||||||
| Impact of currency | (1.1) | (0.6) | % | (4.0) | (1.4) | % | |||||||||||||||||
| Net sales - fiscal 2023 | $ | 209.7 | 14.4 | % | $ | 322.6 | 12.0 | % | |||||||||||||||
Sun and Skin Care net sales for the second quarter of fiscal 2023 increased $26.4, or 14.4%. Organic net sales increased $27.5, or 15.0% driven by strong Sun Care and Men’s Grooming sales. International organic net sales increased 53.4%, driven by higher volumes and pricing in Europe, Latin America and Oceania, while North America organic net sales increased 7.6%, also reflecting higher volumes and pricing.
Sun and Skin Care net sales for the first six months of fiscal 2023 increased $34.5, or 12.0%. Organic net sales increased $38.5, or 13.4%. Organic net sales increases due to favorable price and volumes for Sun Care globally and favorable price and mix in Men’s grooming in North America.
| Segment Profit - Sun and Skin Care | |||||||||||||||||||||||
| Period Ended March 31, 2023 | |||||||||||||||||||||||
| Q2 | % Chg | Six Months | % Chg | ||||||||||||||||||||
| Segment profit - fiscal 2022 | $ | 42.3 | $ | 46.0 | |||||||||||||||||||
| Organic | (2.3) | (5.4) | % | 7.7 | 16.7 | % | |||||||||||||||||
| Impact of currency | (0.1) | (0.2) | % | (0.7) | (1.5) | % | |||||||||||||||||
| Segment profit - fiscal 2023 | $ | 39.9 | (5.6) | % | $ | 53.0 | 15.2 | % | |||||||||||||||
Segment profit for the second quarter of fiscal 2023 was $39.9, a decrease of $2.4, or 5.6%. Organic segment profit decreased $2.3, or 5.4%, driven primarily by higher input costs and increased marketing expense.
Segment profit for the first six months of fiscal 2023 was $53.0, an increase of $7.0, or 15.2%. Organic segment profit increased $7.7, or 16.7%, driven primarily by higher sales volumes and pricing, partially offset by higher A&P expense and mix.
27
Feminine Care
| Net Sales - Feminine Care | |||||||||||||||||||||||
| Period Ended March 31, 2023 | |||||||||||||||||||||||
| Q2 | % Chg | Six Months | % Chg | ||||||||||||||||||||
| Net sales - fiscal 2022 | $ | 59.4 | $ | 131.8 | |||||||||||||||||||
| Organic | 21.0 | 35.4 | % | 29.7 | 22.5 | % | |||||||||||||||||
| Impact of currency | (0.3) | (0.5) | % | (0.5) | (0.4) | % | |||||||||||||||||
| Net sales - fiscal 2023 | $ | 80.1 | 34.9 | % | $ | 161.0 | 22.1 | % | |||||||||||||||
Feminine Care net sales for the second quarter of fiscal 2023 increased $20.7, or 34.9%. Organic net sales increased $21.0, or 35.4%. Organic net sales increase was driven by higher pricing and improved product availability.
Feminine Care net sales for the first six months of fiscal 2023 increased $29.2, or 22.1%. Organic net sales increased $29.7, or 22.5%. The increase in organic net sales was primarily driven by higher pricing and improved product availability.
| Segment Profit - Feminine Care | |||||||||||||||||||||||
| Period Ended March 31, 2023 | |||||||||||||||||||||||
| Q2 | % Chg | Six Months | % Chg | ||||||||||||||||||||
| Segment profit - fiscal 2022 | $ | 1.9 | $ | 10.3 | |||||||||||||||||||
| Organic | 10.4 | 547.5 | % | 14.2 | 137.9 | % | |||||||||||||||||
| Impact of currency | (0.3) | (15.8) | % | (0.7) | (6.8) | % | |||||||||||||||||
| Segment profit - fiscal 2023 | $ | 12.0 | 531.7 | % | $ | 23.8 | 131.1 | % | |||||||||||||||
Feminine Care segment profit for the second quarter of fiscal 2023 was $12.0, an increase of $10.1, or 531.7%. Organic segment profit increased $10.4 or 547.5%, largely driven by higher organic net sales and gross profit.
Feminine Care segment profit for the first six months of fiscal 2023 was $23.8 an increase of $13.5, or 131.1%. Organic segment profit increased $14.2 or 137.9%, primarily due to increased sales volumes and favorable pricing.
General Corporate and Other Expenses
| Quarter Ended March 31, | Six Months Ended March 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Corporate expenses | $ | 17.0 | $ | 17.2 | $ | 32.9 | $ | 28.0 | |||||||||||||||
| Amortization of intangibles | 7.7 | 7.9 | 15.4 | 14.0 | |||||||||||||||||||
| Interest and other expense, net | 23.0 | 14.6 | 37.9 | 30.2 | |||||||||||||||||||
| Restructuring and related costs | $ | 3.0 | 3.7 | 5.8 | 5.9 | ||||||||||||||||||
| Acquisition and integration costs | 2.0 | 1.1 | 4.1 | 7.1 | |||||||||||||||||||
| Sun Care reformulation costs | 0.6 | 0.2 | 1.1 | 3.5 | |||||||||||||||||||
| Defined benefit settlement loss | 7.2 | — | 7.2 | — | |||||||||||||||||||
| VAT settlement costs | — | — | — | 3.4 | |||||||||||||||||||
| Other costs | 0.5 | — | 0.5 | — | |||||||||||||||||||
| General corporate and other expenses | $ | 61.0 | $ | 44.7 | $ | 104.9 | $ | 92.1 | |||||||||||||||
| % of net sales | 10.2 | % | 8.2 | % | 9.8 | % | 9.1 | % | |||||||||||||||
For the second quarter of fiscal 2023, corporate expenses were $17.0, or 2.8% of net sales, compared to $17.2, or 3.1% of net sales. For the first six months of fiscal 2023, corporate expenses were $32.9, or 3.1% of net sales, compared to $28.0, or 2.8% of net sales. For the first six months of fiscal 2023, the increase in corporate expense was primarily due to higher people costs.
28
Liquidity and Capital Resources
As of March 31, 2023, a portion of our cash balances was located outside the U.S. Given our extensive international operations, a significant portion of our cash is denominated in foreign currencies. Refer to Note 14 of Notes to Condensed Consolidated Financial Statements for a discussion of the primary currencies to which the Company is exposed. We manage our worldwide cash requirements by reviewing available funds among the many subsidiaries through which we conduct business and the cost effectiveness with which those funds can be accessed. We generally repatriate a portion of current year earnings from select non-U.S. subsidiaries only if the economic cost of the repatriation is not considered material.
Our cash is deposited with multiple counterparties which consist of major financial institutions. We consistently monitor positions with, and credit ratings of, counterparties both internally and by using outside ratings agencies.
Our total borrowings were $1,447.5 as of March 31, 2023, including $195.2 tied to variable interest rates. Our total borrowings as of September 30, 2022 were $1,424.0. We had outstanding borrowings of $176.0 under the Revolving Credit Facility as of March 31, 2023. Taking into account outstanding letters of credit of $5.9, as of March 31, 2023, $243.1 was available under the Revolving Credit Facility. Additionally, we had other short term borrowings, of $21.5 and $19.0 as of March 31, 2023 and September 30, 2022, respectively, related to our international subsidiaries, of which $19.2 and $19.0 were variable-rate borrowings and recorded in Notes Payable.
On February 6, 2023, we amended our Revolving Credit Facility to transition from using the London Interbank Offered Rate (“LIBOR”) to the Secured Overnight Financing Rate (“SOFR”) as LIBOR will no longer be available June 30, 2023.
Historically, we have generated, and expect to continue to generate, favorable cash flows from operations. Our cash flows are affected by the seasonality of our Sun Care businesses, typically resulting in higher net sales and increased cash generated in the second and third quarter of each fiscal year. We believe our cash on hand, cash flows from operations and borrowing capacity under the Revolving Credit Facility will be sufficient to satisfy our future working capital requirements, interest payments, R&D activities, capital expenditures, and other financing requirements for at least the next 12 months. We will continue to monitor our cash flows, spending and liquidity needs.
To date, the COVID-19 pandemic has not had a significant impact on our liquidity or capital resources. However, the COVID-19 pandemic has led to disruption and volatility in the global capital markets which could impact our capital resources and liquidity in the future. For further information, please refer to Item 1A. Risk Factors in Part I of our 2022 Annual Report.
Short-term financing needs primarily consist of working capital requirements and interest payments on our long-term debt. Long-term financing needs will depend largely on potential growth opportunities, including acquisition activity and repayment or refinancing of our long-term debt obligations. Our long-term liquidity may be influenced by our ability to borrow additional funds, renegotiate existing debt, and raise equity under terms that are favorable to us. We may, from time-to-time, seek to repurchase shares of our common stock. Such repurchases, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors.
As of March 31, 2023, we were in compliance with the provisions and covenants associated with our debt agreements.
29
Cash Flows
A summary of our cash flow activities is provided in the following table:
| Six Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Net cash from (used by): | |||||||||||
| Operating activities | $ | 1.9 | $ | (39.9) | |||||||
| Investing activities | (20.0) | (325.7) | |||||||||
| Financing activities | (29.0) | 78.3 | |||||||||
| Effect of exchange rate changes on cash | 13.6 | (3.8) | |||||||||
| Net decrease in cash and cash equivalent | $ | (33.5) | $ | (291.1) | |||||||
Operating Activities
Cash flow from operating activities was $1.9 during the first six months of fiscal 2023, compared to cash used of $39.9 during the prior year period. The increase in cash flows versus the same period in the prior year was driven by a lower net working capital requirements.
Investing Activities
Net cash used by investing activities was $20.0 during the first six months of fiscal 2023, compared to $325.7 used during the prior year period. Capital expenditures were $18.8 during the first six months of fiscal 2023, compared to $25.0 in the prior year period. We completed the Acquisition for $309.4, net of cash acquired, in the prior year period. Additionally, we collected $5.0 of proceeds from the sale of the Infant and Pet Care business in the prior year period.
Financing Activities
Net cash (used by) from financing activities was ($29.0) during the first six months of fiscal 2023, compared to a source of $78.3 in the prior year period. During the first six months of fiscal 2023, we had net borrowings of $21.0 under the Revolving Credit Facility, compared to $179.0 in the prior year period. We repurchased $30.0 of our common stock under our 2018 Board authorization to repurchase our common stock (the “Repurchase Plan”) compared to $75.4 in the prior year period. Dividend payments totaled $16.1 in the first six months of fiscal 2023, compared to $16.7 in the prior year period. We had financing outflows for employee equity awards held for taxes totaling $8.1 in the first six months of fiscal 2023, compared to $9.7 in the prior year period.
Share Repurchases
During the first six months of fiscal 2023, we repurchased 0.8 shares of our common stock for $30.0. We have 5.7 shares remaining under the Repurchase Plan as of March 31, 2023. Future share repurchases, if any, would be made in the open market, privately negotiated transactions or otherwise, in such amounts and at such times as we deem appropriate based upon prevailing market conditions, business needs and other factors.
Dividends
On November 3, 2022, the Board declared a quarterly cash dividend of $0.15 per common share for the fourth fiscal quarter of 2022. The dividend was paid on January 4, 2023 to shareholders of record as of the close of business on November 29, 2022.
On February 3, 2023, the Board declared a quarterly cash dividend of $0.15 per common share for the first fiscal quarter of 2023. The dividend was paid on April 5, 2023 to stockholders of record as of the close of business on March 8, 2023.
On May 8, 2023, the Board declared a quarterly cash dividend of $0.15 per common share for the second fiscal quarter of 2023. The dividend will be payable on July 6, 2023 to stockholders of record as of the close of business on June 7, 2023.
Dividends declared during the six months ended March 31, 2023 totaled $16.2. Payments made for dividends during the six months ended March 31, 2022 totaled $16.1.
30
Commitments and Contingencies
Contractual Obligations
As of March 31, 2023, we had outstanding borrowings of $176.0 under the Revolving Credit Facility. As of March 31, 2023, future minimum repayments of debt were: $176.0 in fiscal 2025, $750.0 in fiscal 2028 and $500.0 in fiscal 2029.
There have been no other material changes in our contractual obligations since the presentation in our 2022 Annual Report.
Critical Accounting Policies
Our critical accounting policies and estimates are fully described in our 2022 Annual Report. The preparation of these financial statements requires us to make estimates and assumptions. These estimates and assumptions can be subjective and complex, and consequently, actual results could differ from those estimates. There have been no significant changes to our critical accounting policies and estimates since September 30, 2022.
31
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
(Amounts in millions)
The market risk inherent in our financial instruments and positions represents the potential loss arising from adverse changes in currency rates, commodity prices, and interest rates. At times, we enter into contractual arrangements (derivatives) to reduce these exposures. For further information on our foreign currency derivative instruments, refer to Note 14 of Notes to Condensed Consolidated Financial Statements. As of March 31, 2023, there were no open derivative or hedging instruments for future purchases of raw materials or commodities. Our exposure to interest rate risk relates primarily to our variable-rate debt instruments, which currently bear interest based on SOFR plus margin. As of March 31, 2023, our outstanding variable-rate debt included $195.2 related to our Revolving Credit Facility and international, variable-rate notes payable. Assuming a one-percent increase in the applicable interest rates, annual interest expense on these variable-rate debt instruments would increase approximately $2.0.
There have been no material changes in our assessment of market risk sensitivity since our presentation of Quantitative and Qualitative Disclosures About Market Risk in our 2022 Annual Report.
32
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Exchange Act, is recorded, processed, summarized and reported within the specified time periods, and that such information is accumulated and communicated to management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosure.
Our management, with the participation of our CEO and CFO, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2023. Based on that evaluation, our CEO and CFO concluded that, as of that date, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended March 31, 2023 that have materially affected, or are likely to materially affect, our internal control over financial reporting.
33
PART II - OTHER INFORMATION
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
The following table sets forth the purchases of our Company’s securities by the Company and any affiliated purchasers within the meaning of Rule 10b-18(a)(3) (17 CFR 240.10b-18(a)(3)) during the second quarter of fiscal 2023:
| Period | Total Number of Shares Purchased (1) (2) | Average Price Paid per share (3) | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2) | Maximum Number that May Yet Be Purchased Under the Plans or Programs | ||||||||||||||||||||||
| January 1 to 31, 2023 | 119,560 | $ | 40.23 | 119,560 | 5,978,169 | |||||||||||||||||||||
| February 1 to 28, 2023 | 105,294 | 43.44 | 99,720 | 5,878,449 | ||||||||||||||||||||||
| March 1 to 31, 2023 | 133,396 | 41.73 | 133,396 | 5,745,053 | ||||||||||||||||||||||
(1)Includes 5,574 shares purchased during the quarter relate to the surrender to the Company of shares of common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock equivalent awards.
(2)In January 2018, our Board authorized a repurchase of up to 10 million shares of our Company’s common stock. This authorization replaced the prior share repurchase authorization of May 2015. During the second quarter of fiscal 2023, we repurchased 352,676 shares under this authorization.
(3)Includes $0.02 per share of brokerage fee commissions.
34
Item 6. Exhibits.
| Exhibit Number | Exhibit | ||||
| 3.1 | |||||
| 3.2 | |||||
| 3.3 | |||||
| 10.1 | |||||
| 10.2 | |||||
| 10.3 | |||||
| 10.4 | |||||
| 10.5 | |||||
| 10.6 | |||||
| 31.1* | |||||
| 31.2* | |||||
| 32.1** | |||||
| 32.2** | |||||
| 101 | The following materials from the Edgewell Personal Care Company Quarterly Report on Form 10-Q formatted in inline eXtensible Business Reporting Language (“iXBRL”): (i) the Condensed Consolidated Statements of Earnings and Comprehensive Income for the three and six months ended March 31,2023 and 2022, (ii) the Condensed Consolidated Balance Sheets at March 31, 2023 and September 30, 2022, (iii) the Condensed Consolidated Statements of Cash Flows for the three and six months ended March 31, 2023 and 2022, (iv) the Condensed Consolidated Statements of Shareholder’s Equity for the three and six months ended March 31, 2023 and 2022 and (v) Notes to Condensed Consolidated Financial Statements. The financial information contained in the XBRL-related documents is “unaudited” and “unreviewed.” | ||||
*Filed herewith.
** Furnished herewith
35
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| EDGEWELL PERSONAL CARE COMPANY | |||||||||||
| Registrant | |||||||||||
| By: | /s/ Daniel J. Sullivan | ||||||||||
| Daniel J. Sullivan | |||||||||||
| Chief Financial Officer | |||||||||||
| (principal financial officer) | |||||||||||
| Date: | May 9, 2023 | ||||||||||
36
Exhibit 31.1
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Rod R. Little, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Edgewell Personal Care Company;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: May 9, 2023
| /s/ Rod R. Little | ||
| Rod R. Little | ||
| Chief Executive Officer | ||
| (principal executive officer) | ||
Exhibit 31.2
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Daniel J. Sullivan, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Edgewell Personal Care Company;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: May 9, 2023
| /s/ Daniel J. Sullivan | ||
| Daniel J. Sullivan | ||
| Chief Financial Officer | ||
| (principal financial officer) | ||
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
The undersigned officer of Edgewell Personal Care Company (the "Company") hereby certifies to his knowledge that the Company's quarterly report on Form 10-Q for the period ended March 31, 2023 (the "Report"), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) of 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: May 9, 2023
| /s/ Rod R. Little | ||
| Rod R. Little | ||
| Chief Executive Officer | ||
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
The undersigned officer of Edgewell Personal Care Company (the "Company") hereby certifies to his knowledge that the Company's quarterly report on Form 10-Q for the period ended March 31, 2023 (the "Report"), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: May 9, 2023
| /s/ Daniel J. Sullivan | ||
| Daniel J. Sullivan | ||
| Chief Financial Officer | ||